NuvoBio’s Post

Pleno Inc., a San Diego, CA-based clinical and multi-omics diagnostics company, raised $25M in Series B funding. Backers included Deerfield Management, Foresite Capital and Medical Excellence Capital. Pleno is an early-stage startup company developing the RAPTORTM multi-omic instrument platform to improve biological target detection and enable various life science applications. https://lnkd.in/guciAtX8

At the 7th Annual Life Science Summit by BioStock, we had the pleasure of speaking with Magnus Holm from Peppermint Venture Partners GmbH, a leading venture capital firm based in Berlin.   Peppermint Venture Partners (PVP) is a Berlin-based private venture capital firm specializing in investments in early-stage companies.   PVP focuses on innovative medical technology, diagnostics, digital health, and, increasingly, labtech tools and services. Its newly launched LIIDO fund aims to invest in emerging market leaders in life science tools and services. With a target volume of €100 million, LIIDO will concentrate on technology-driven European companies that already have innovative products or services in the market and are generating initial revenue.

Watch my interview With Magnus Holm from Peppermint Venture Partners!

👏 Former SETsquared Scale-Up Programme member, iFAST Diagnostics, has announced the closure of its successful $6.5m (£5m) seed round, allowing them to bring their rapid antimicrobial susceptibility testing (AST) test to the UK market as soon as early 2025. While traditional AST methods require 48 to 72 hours, the iFAST system reduces this testing time to under three hours - delivering the potential to improve patient outcomes whilst making sure that patients receive the right treatment at the right time. To support this mission, iFAST has seen significant investment through its recent oversubscribed round, led by KHP Ventures, the first NHS-anchored venture fund, alongside existing investors QantX, UKI2S (Managed by Future Planet Capital, Kadmos, and several angel investors. New investors, EInk, Raw Ventures, and OKG Capital also contributed to the round. Get the full story 👉 https://lnkd.in/gDYNxZvf #MedTech #Medicine #AMR #AntibioticResistance

YPOG advised lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund, and HTGF | High-Tech Gründerfonds also participated in the investment.   The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.   Congratulations to our client Vesalius and all parties involved!   The YPOG team was led by Martin Schaper and included Dr. Lutz Schreiber, Benjamin Müller, Matthias Treude as well as Cyra Dittberner.   ➡ Link to the press release in the comments below.   #YPOG #PartnersOfGamechangers #VentureCapital #Growth #Funds #Transactions

XGEN Venture Announces Final Closing of €180M ($190M) Life Sciences Fund https://lnkd.in/eDxw73i9 XGEN Venture Paolo Fundarò Federica Draghi Daniele Scarinci Mariagiulia Davide More European life science business news at [LSE] Life-Sciences-Europe.com __

🎥 Investment Manager, Lee Lindley explains a little more about why Mercia Ventures led a £8.5million fundraise into Wobble Genomics Ltd, and details how its groundbreaking technology could be transformational in helping to change people's outcomes. Full video ➡️ https://hubs.li/Q02ZFYkQ0 #VCT #WhyWeInvested #Genomics #RNA #Investment #VentureCapital

Looking forward to conversations around therapies and technology progressing with improved investor sentiment, albeit with caution! Investing? How commercially viable is the science? What are the product development/CMC and regulatory/clinical risks? What is the competitive landscape? Fundraising? Does your pitch deck and data room position your company to be as investable as possible? Promising non-clinical data? How to turn that into a commercial product? What is the best product development and regulatory strategy? Growing pains? Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another! Let’s connect and discuss how Boyds can help! #REAIBoston2024 #BiotechweekBoston

We are thrilled to have secured £6.6M, led by M Ventures, to commercialise our disruptive Amperia technology for simplified at-line protein analysis. In the funding round, M Ventures (the strategic, corporate venture capital arm of science and technology company Merck), is joined by new investors BioProcess360 Partners and Untitled Ventures, along with BGF, R42 Group and other existing investors. We welcome Oliver Hardick of M Ventures and Chris Major of BioProcess 360 Partners to our new Board of Directors. “We are delighted to have the support of our investment partners to advance our mission to provide scientists with critical real-time data at the point of need,” says Ruizhi Wang, CEO of Abselion. “The Amperia RED technology delivers the accuracy, speed and agility required for insights that enable confident decision-making, driving bioprocess optimisation and innovation.” Read the full press release: https://lnkd.in/g69deUEY #drugdevelopment #bioprocessing #innovation